FDA Approves TNKase for Acute Ischemic Stroke
By Lori Solomon HealthDay Reporter
.jpg?width=1200)
THURSDAY, March 6, 2025 -- The U.S. Food and Drug Administration has approved TNKase (tenecteplase), a thrombolytic or clot-dissolving agent, for the treatment of acute ischemic stroke in adults.
TNKase is delivered as a single five-second intravenous bolus. This is considerably faster than the standard of care, Activase (alteplase), which is administered as an intravenous bolus followed by a 60-minute infusion. Genentech, the manufacturer of TNKase, says a new 25-mg vial configuration will be available in the coming months.
The approval is based on a study comparing TNKase to Activase in patients with acute ischemic stroke who presented with a disabling neurological deficit. Results show that TNKase was comparable to Activase in terms of efficacy and safety.
Stroke affects more than 795,000 people each year in the United States. It is the leading cause of long-term disability and the fifth leading cause of death. Since brain damage occurs and progresses rapidly during an acute ischemic stroke, immediate, fast-acting medical care is vital.
"Today's approval is a significant step forward and underscores our commitment to advancing stroke treatment options for patients," Levi Garraway, M.D., Ph.D., the chief medical officer and head of global product development at Genentech, said in a statement. "TNKase provides a faster and simpler administration, which can be critical for anyone who is dealing with an acute stroke."
Approval of TNKase was granted to Genentech.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
Posted March 2025
Read this next
FDA Approves Sublingual, Nonopioid Daily Treatment for Fibromyalgia, Tonmya
WEDNESDAY, Aug. 20, 2025 -- The U.S. Food and Drug Administration has approved Tonmya (cyclobenzaprine hydrochloride) sublingual tablets for the treatment of fibromyalgia in...
Seniors Neglecting Steps To Protect Heart Health, Study Says
WEDNESDAY, Aug. 20, 2025 — Seniors with known heart-related problems aren’t doing a very good job taking steps to protect their health, a new study says. Older folks...
Tight Blood Pressure Control Both Healthy And Cost-Effective, Projections Say
WEDNESDAY, Aug. 20, 2025 — Tight control over blood pressure is not only good for patients, but is also cost-effective health care, a new study says. Controlling blood...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.